Weight-loss drugs have “little or no effect” on reducing the risk of cancers related to obesity, according to a new study.

A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D) or ...

Popular weight-loss drugs “probably have little or no effect” on a person’s risk of developing one of the 13 obesity-related ...